Nasus Pharma Ltd (NSRX) — Institutional Holders, Q2 2026
10 institutional investment managers reported a NSRX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $7.5M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
NSRX in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- CITADEL ADVISORSNew · +22,004 sh+$77.0K
- XTX Topco LtdNew · +16,640 sh+$58.2K
- Cable Car CapitalAdded · +14,083 sh+$49.3K
- RENAISSANCE TECHNOLOGIESNew · +12,200 sh+$42.7K
- Caitong International Asset Management , LtdNew · +4 sh+$14.00
Biggest sellers
- Empery Asset ManagementSold out · -45,803 sh-$160.3K
- HRT FINANCIALSold out · -38,897 sh-$136.1K
- UBS Group AGSold out · -3,094 sh-$10.8K
- MORGAN STANLEYTrimmed · -1,000 sh-$3.5K
NSRX 13F holders ranked 1–10 of 10
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | BALYASNY ASSET MANAGEMENT L.P.#1 · 898,473 sh | 898,473 | $3.1M | <0.01% | 0.0% |
| 2 | Cable Car Capital#2 · 616,081 sh | 616,081 | $2.2M | 0.05% | +2.3% |
| 3 | Velan Capital Investment Management#3 · 359,390 sh | 359,390 | $1.3M | 0.77% | 0.0% |
| 4 | Hudson Bay Capital Management#4 · 134,771 sh | 134,771 | $471.7K | <0.01% | 0.0% |
| 5 | Bleichroeder#5 · 89,848 sh | 89,848 | $314.5K | 0.06% | 0.0% |
| 6 | CITADEL ADVISORS#6 · 22,004 sh | 22,004 | $77.0K | 0.00% | New |
| 7 | XTX Topco Ltd#7 · 16,640 sh | 16,640 | $58.2K | <0.01% | New |
| 8 | RENAISSANCE TECHNOLOGIES#8 · 12,200 sh | 12,200 | $42.7K | <0.01% | New |
| 9 | MORGAN STANLEY#9 · 1,000 sh | 1,000 | $3.5K | 0.00% | -50.0% |
| 10 | Caitong International Asset Management , Ltd#10 · 4 sh | 4 | $14.00 | 0.00% | New |
Funds that sold out of NSRX in Q2 2026 (3)
Held NSRX at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| Empery Asset Management45,803 sh | 45,803 | $101.7K |
| HRT FINANCIAL38,897 sh | 38,897 | $86.0K |
| UBS Group AG3,094 sh | 3,094 | $6.9K |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.